“Hopefully with the publication of this journal, it can help advance the development of global health science, and contribute to our fight against Covid-19,” he said.
The development of the Nusantara vaccine had caused a prolonged controversy in the past. The fate of the vaccine was decided through a memorandum of understanding (MoU) between the Food and Drug Supervisory Agency (BPOM), the Health Ministry and the Indonesian Army (TNI AD) on April 19.
The MoU agreed that the process of taking blood samples from volunteers at the Gatot Soebroto Army Hospital in Jakarta was only carried out for research purpose. This means that it was not done as part of a clinical trial process to obtain BPOM distribution license, but only as a form of public service. (rr)